California State Teachers Retirement System cut its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 8.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 420,756 shares of the pharmaceutical company’s stock after selling 37,530 shares during the quarter. California State Teachers Retirement System owned 0.17% of Vertex Pharmaceuticals worth $63,972,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently made changes to their positions in the business. Smithfield Trust Co. bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth approximately $135,000. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of Vertex Pharmaceuticals by 15.4% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 988 shares of the pharmaceutical company’s stock worth $127,000 after acquiring an additional 132 shares during the last quarter. FNY Partners Fund LP lifted its holdings in shares of Vertex Pharmaceuticals by 900.0% in the 2nd quarter. FNY Partners Fund LP now owns 1,000 shares of the pharmaceutical company’s stock worth $128,000 after acquiring an additional 900 shares during the last quarter. FNY Managed Accounts LLC bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth approximately $162,000. Finally, Fuller & Thaler Asset Management Inc. bought a new stake in shares of Vertex Pharmaceuticals in the 3rd quarter worth approximately $198,000. Institutional investors and hedge funds own 93.33% of the company’s stock.

A number of equities research analysts have recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and issued a $195.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, October 27th. Cowen restated a “buy” rating and issued a $200.00 price objective on shares of Vertex Pharmaceuticals in a report on Monday. Vetr downgraded shares of Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $181.00 target price on the stock. in a research note on Monday, September 4th. BidaskClub downgraded shares of Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, August 19th. Finally, Maxim Group reaffirmed a “buy” rating and issued a $195.00 target price on shares of Vertex Pharmaceuticals in a research note on Thursday, October 26th. One research analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-four have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $173.22.

Vertex Pharmaceuticals Incorporated (VRTX) opened at $144.80 on Thursday. The company has a current ratio of 3.28, a quick ratio of 3.14 and a debt-to-equity ratio of 0.01. The stock has a market cap of $36,620.00, a price-to-earnings ratio of 236.13, a price-to-earnings-growth ratio of 3.39 and a beta of 1.57. Vertex Pharmaceuticals Incorporated has a 1 year low of $71.46 and a 1 year high of $167.85.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Wednesday, October 25th. The pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.04 by $0.49. The business had revenue of $578.20 million for the quarter, compared to the consensus estimate of $522.07 million. Vertex Pharmaceuticals had a net margin of 8.53% and a return on equity of 9.23%. The company’s quarterly revenue was up 39.7% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.16 EPS. equities research analysts predict that Vertex Pharmaceuticals Incorporated will post 0.76 earnings per share for the current year.

In other Vertex Pharmaceuticals news, CEO Jeffrey M. Leiden sold 125,000 shares of the business’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $141.35, for a total transaction of $17,668,750.00. Following the transaction, the chief executive officer now directly owns 237,407 shares of the company’s stock, valued at approximately $33,557,479.45. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Stuart A. Arbuckle sold 221 shares of the business’s stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $147.29, for a total transaction of $32,551.09. The disclosure for this sale can be found here. Over the last three months, insiders have sold 343,519 shares of company stock worth $49,488,660. Insiders own 1.80% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Vertex Pharmaceuticals Incorporated (VRTX) Shares Sold by California State Teachers Retirement System” was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was illegally copied and republished in violation of international copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/vertex-pharmaceuticals-incorporated-vrtx-shares-sold-by-california-state-teachers-retirement-system/1763256.html.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.

Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).

Institutional Ownership by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.